Rezolute, Inc. (RZLT)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put RZLT beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisThis stock is highly volatile — it swings about 2% on a typical day and fell roughly 87% in its worst 12-month stretch.
View RiskRZLT’s bet rests on advancing ersodetug and its phase three tumor study. The fourth-quarter fiscal 2026 result missed consensus, with EPS down 42.9%. The company has no clear valuation multiple because earnings remain unprofitable. The price is roughly in line with forecast growth, but a clean peer comparison is unavailable. A next-quarter earnings miss carries a 51% probability in our model. That risk matters after the latest reported earnings miss. Peer multiples imply a price about 57% above where it trades. Our standing thesis remains intact; this read is provisional.
Trailing returns as of 2026-10-29. RZLT is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 12 analysts currently covering RZLT (as of Oct 2026).
Based on 3 Wall Street analysts offering 12-month price targets for RZLT in the last 4 months.
Continue this research
Compare RZLT with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| RZLT Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 1 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put RZLT next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Complete enrollment and report topline results for upLIFT tumor HI study
Enrollment completion supports growth in tumor HI study.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
Current $4.12
The last 12 months of price, then the range of analyst 12-month targets from today’s $4.12.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.

Advances: Advance ersodetug approval for congenital hyperinsulinism
Upgrade indicates confidence in trial data and growth potential.

Advances: Complete enrollment and report topline results for upLIFT tumor HI study
Positive trial data supports growth objectives.

Insider buying indicates confidence in the company's future.